In a report released today, Irina Rivkind Koffler from Mizuho Securities maintained a Hold rating on Allergan (NYSE: AGN). The company’s shares opened today at $162.97.
Rivkind Koffler wrote:
“We raise PT to $176 from $150 on stronger Botox expectations in both migraine and cosmetic indications, and view recent investor activism as positive to AGN.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 13.9% and a 48.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Adamas Pharmaceuticals, and Eagle Pharmaceuticals.
Currently, the analyst consensus on Allergan is Moderate Buy and the average price target is $212.10, representing a 30.1% upside.
In a report issued on May 31, Piper Jaffray also reiterated a Hold rating on the stock with a $161 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $256.80 and a one-year low of $142.81. Currently, Allergan has an average volume of 2.84M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.
